BULEVIRTIDE

BULEVIRTIDE was reported 96 times

BULEVIRTIDE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HEPATITIS D ANTIBODY POSITIVE 1 0.5000
1 HEPATITIS D RNA POSITIVE 3 0.3333
2 HEPATITIS D 6 0.0714
3 HEPATIC FIBROSIS MARKER INCREASED 1 0.0333
4 TOTAL BILE ACIDS INCREASED 2 0.0137
5 HEPATITIS B DNA ASSAY POSITIVE 1 0.0078
6 NASAL CYST 1 0.0071
7 INJECTION SITE DERMATITIS 1 0.0069
8 BILE ACIDS INCREASED 1 0.0056
9 SPONTANEOUS BACTERIAL PERITONITIS 1 0.0041
10 INFUSION SITE THROMBOSIS 1 0.0037
11 ASTROCYTOMA 1 0.0025
12 PORTAL HYPERTENSIVE GASTROPATHY 1 0.0018
13 LICHEN PLANUS 4 0.0017
14 BLOOD BILIRUBIN DECREASED 1 0.0016
15 HEPATITIS B DNA INCREASED 1 0.0015
16 CUTANEOUS SYMPTOM 1 0.0015
17 HEPATIC FIBROSIS 5 0.0015
18 ALANINE AMINOTRANSFERASE ABNORMAL 3 0.0014
19 PORTAL HYPERTENSION 4 0.0013
20 BLOOD ALBUMIN INCREASED 1 0.0011
21 VIROLOGIC FAILURE 6 0.0011
22 VIRAL LOAD INCREASED 4 0.0010
23 SUSPECTED PRODUCT CONTAMINATION 1 0.0010
24 LIVER TRANSPLANT 3 0.0008
25 BLOOD BILIRUBIN ABNORMAL 1 0.0008
26 HEPATIC CIRRHOSIS 14 0.0007
27 VIRAEMIA 1 0.0007
28 VARICES OESOPHAGEAL 2 0.0007
29 PORTAL VEIN THROMBOSIS 2 0.0006
30 HYPOMANIA 2 0.0005
31 HEPATOCELLULAR CARCINOMA 4 0.0005
32 VITREOUS DETACHMENT 1 0.0005
33 OESOPHAGEAL VARICES HAEMORRHAGE 1 0.0005
34 CHRONIC GASTRITIS 1 0.0004
35 ACUTE PSYCHOSIS 1 0.0004
36 ABNORMAL UTERINE BLEEDING 1 0.0004
37 DUODENITIS 1 0.0003
38 IMMUNOSUPPRESSANT DRUG LEVEL INCREASED 1 0.0003
39 B-CELL LYMPHOMA 1 0.0003
40 TYPE I HYPERSENSITIVITY 1 0.0003
41 DEPRESSIVE SYMPTOM 1 0.0003
42 CHRONIC SINUSITIS 1 0.0003
43 INTERNATIONAL NORMALISED RATIO DECREASED 1 0.0002
44 SUICIDAL BEHAVIOUR 1 0.0002
45 PANCYTOPENIA 10 0.0002
46 PANCREATITIS ACUTE 4 0.0002
47 PROTHROMBIN TIME PROLONGED 1 0.0002
48 HEPATIC FAILURE 5 0.0002
49 CHOLANGITIS 1 0.0002
50 HEPATITIS ACUTE 1 0.0002
51 METASTASES TO LYMPH NODES 1 0.0001
52 INJURY ASSOCIATED WITH DEVICE 3 0.0001
53 DRUG-INDUCED LIVER INJURY 4 0.0001
54 SHOCK HAEMORRHAGIC 1 0.0001
55 IRON DEFICIENCY ANAEMIA 1 0.0001
56 HEPATIC ENCEPHALOPATHY 1 0.0001
57 APPENDICITIS 1 0.0001
58 VITAMIN D DEFICIENCY 1 0.0001
59 LIVER FUNCTION TEST INCREASED 2 0.0001
60 TREATMENT NONCOMPLIANCE 5 0.0001
61 TRANSAMINASES INCREASED 2 0.0001
62 REBOUND EFFECT 1 0.0001
63 POLYNEUROPATHY 1 0.0001
64 DERMATITIS ALLERGIC 1 0.0001
65 LYMPHOPENIA 1 0.0001
66 VIRAL INFECTION 2 0.0001
67 LEUKOPENIA 3 0.0001
68 HEAD DISCOMFORT 1 0.0001
69 CHOLESTASIS 1 0.0001
70 FULL BLOOD COUNT DECREASED 1 0.0000
71 INJECTION SITE WARMTH 1 0.0000
72 LIVER DISORDER 2 0.0000
73 THROMBOCYTOPENIA 5 0.0000
74 HEPATIC CANCER 1 0.0000
75 LOCALISED INFECTION 1 0.0000
76 INFLUENZA LIKE ILLNESS 3 0.0000
77 RESPIRATORY DISTRESS 1 0.0000
78 INTENTIONAL DOSE OMISSION 1 0.0000
79 EPILEPSY 1 0.0000
80 ALANINE AMINOTRANSFERASE INCREASED 2 0.0000
81 HEPATIC ENZYME INCREASED 2 0.0000
82 INJECTION SITE MASS 1 0.0000
83 HEPATIC FUNCTION ABNORMAL 1 0.0000
84 DISEASE PROGRESSION 3 0.0000
85 MATERNAL EXPOSURE DURING PREGNANCY 2 0.0000
86 NEUTROPENIA 3 0.0000
87 PANCREATITIS 1 0.0000
88 ASTHENIA 7 0.0000
89 DISTURBANCE IN ATTENTION 1 0.0000
90 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 1 0.0000
91 BONE PAIN 1 0.0000
92 INJECTION SITE PRURITUS 1 0.0000
93 INJECTION SITE REACTION 1 0.0000
94 SLEEP DISORDER 1 0.0000
95 DYSGEUSIA 1 0.0000
96 INJECTION SITE SWELLING 1 0.0000
97 TREATMENT FAILURE 1 0.0000
98 RENAL IMPAIRMENT 1 0.0000
99 COVID-19 2 0.0000
100 BREAST CANCER 1 0.0000
101 HAEMOGLOBIN DECREASED 1 0.0000
102 HAEMORRHAGE 1 0.0000
103 PLATELET COUNT DECREASED 1 0.0000
104 WHITE BLOOD CELL COUNT DECREASED 1 0.0000
105 INJECTION SITE ERYTHEMA 1 0.0000
106 PRURITUS 3 0.0000
107 PRODUCT QUALITY ISSUE 1 0.0000
108 CONDITION AGGRAVATED 2 0.0000
109 PERIPHERAL SWELLING 1 0.0000
110 FATIGUE 5 0.0000
111 DRUG INTERACTION 1 0.0000
112 URTICARIA 1 0.0000
113 URINARY TRACT INFECTION 1 0.0000
114 HYPERSENSITIVITY 1 0.0000
115 DRUG INEFFECTIVE 7 0.0000
116 BLOOD GLUCOSE INCREASED 1 0.0000
117 OFF LABEL USE 4 0.0000
118 DEPRESSION 1 0.0000
119 DECREASED APPETITE 1 0.0000
120 PRODUCT USE IN UNAPPROVED INDICATION 1 0.0000
121 DYSPNOEA 2 0.0000
122 PRODUCT DOSE OMISSION ISSUE 1 0.0000
123 HEADACHE 2 0.0000
124 PYREXIA 1 0.0000
125 PAIN 1 0.0000
126 NAUSEA 1 0.0000
127 DEATH 1 0.0000